Pityriasis Versicolor in Children and Adolescents: an Update

Total Page:16

File Type:pdf, Size:1020Kb

Pityriasis Versicolor in Children and Adolescents: an Update Current Fungal Infection Reports (2019) 13:157–168 https://doi.org/10.1007/s12281-019-00360-8 FUNGAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE (A BONIFAZ AND M PEREIRA, SECTION EDITORS) Pityriasis Versicolor in Children and Adolescents: an Update Karen Adilene Camargo-Sánchez1 & Mirna Toledo-Bahena1 & Carlos Mena-Cedillos1 & Erika Ramirez-Cortes2 & Sonia Toussaint-Caire3 & Adriana Valencia-Herrera1 & Marcela Salazar-García4 & Alexandro Bonifaz5 Published online: 7 November 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Pityriasis versicolor (PV) is a superficial mycosis that it can occur at any age, even in newborns. In this review, we will describe epidemiological data, mycological characteristics of yeast, pathogenesis and clinical characteristics of the disease, different diagnostic resources, and the current recommendations for treatment. Recent Findings The typical morphology and topography of PV allow us to make a quick diagnosis, but atypical presentations have been described. Diagnostic tools, such as dermoscopy, can also reveal patterns that allow the evaluation of characteristics of scales and pigment in lesions. The discovery of new species and new mechanisms of interaction with the host has broadened the panorama of aetiological possibilities. Summary Although PV is a common disorder, extensive research is necessary to better understand the pathophysiology of the disease, immunological characteristics of the pathogen-host relationship and resources needed to precisely diagnose the disease, treat the disease, and avoid its chronic and recurrent course. Keywords Pityriasis versicolor . Malassezia spp. children . adolescents . tinea versicolor . superficial mycoses . hypopigmented lesions Introduction new species of Malassezia as etiological agents and mecha- nisms of interaction with the host, as well as new treatment Superficial mycoses are frequent entities in daily medical opportunities. In this review, we will focus on these findings practice, so their recognition is important. Pityriasis versicolor and also describe the concepts regarding epidemiology, diag- (PV) is one of them and its most common manifestation facil- nosis, treatment and prognosis. itates diagnosis; however, there are new clinical forms de- scribed that extend the differential diagnoses of the disorder, Concept This article is part of the Topical Collection on Fungal Infections of Skin and Subcutaneous Tissue PV is a superficial (restricted to the stratum corneum), chronic * and relapsing mycosis caused by yeasts of the genus Adriana Valencia-Herrera •• [email protected] Malassezia [1 ]. The name PV derives from the fine desqua- mation, appearing similar to bran and being present in the lesions that characterize this condition, which can be 1 Department of Dermatology, Hospital Infantil de México Federico Gómez, Dr. Márquez 162, Col. Doctores, Del. Cuauhtémoc, hypopigmented or hyperpigmented. PV has also been called CP 06720 Ciudad de México, México tinea versicolor, mainly in Anglo-Saxon literature, because the – 2 Hospital Star Médica Infantil Privado, Ciudad de México, México aetiological agent is called Microsporon furfur [2 4]. 3 Division of Dermatology, Hospital General Dr. Manuel Gea González, Ciudad de México, México 4 Department of Biomedical Research, Hospital Infantil de México Epidemiology Federico Gómez, Ciudad de México, México 5 Department of Dermatology and Mycology, Hospital General de PV is a cosmopolitan entity but is predominately found in México Dr. Eduardo Liceaga, Ciudad de, MéxicoMéxico tropical regions where it affects up to 40–50% of individuals 158 Curr Fungal Infect Rep (2019) 13:157–168 and tends to recur in summer, unlike regions such as Sweden The genus Malassezia currently includes 18 species that where a frequency of up to 0.5% has been reported [5, 6]. are present on the skin, 10 of which have been found on Although no recent studies have been performed on the dis- human skin, while the remaining 8 species were isolated from ease, Heidrich et al. reported a 0.3% decrease in the preva- homeothermic animals, as shown in Table 2 [4, 28, 29]. lence per year [1••]. Although M. furfur was previously considered a unique aetiological agent of PV,we currently know that the frequency Age of M. furfur as a causative agent varies across different species based on reports from multiple studies according to the region PV can occur at any age and some reports indicate its emer- studied, the year of the study and the methods used to identify gence even in the neonatal period in association with factors Malassezia species; for example: such as prematurity, hospitalization in intensive care units, – high humidity in incubators, direct contact with affected fam- In Argentina in 2012, M. sympodialis and M. globosa ily members and persistence of maternal hormones. PV is were reported to have the highest frequencies at 51% more common in adolescents and young adults. The predom- and 40%, respectively [26]. – inant age group varies in different studies, with some patients In Adana, Turkey, in 2009, M. globosa was documented aged older than 30 years [1••, 7–11]. In infants, frequencies in 47.7% of PV cases, M. furfur was documented in ranging from 3.7 to 31% have been described [12, 13]. 36.4% of PV cases and M. slooffiae was documented in 15.9% of PV cases [31]. – In 2014, in Iran, M. globosa was isolated in 65.1% of PV Gender cases and M. obtusa was isolated in 17.4% of PV cases [17]. PV is more common in men, which has been attributed to – In 28 students in northeast Iran, M. restricta was the most increased sebaceous activity [1••]. However, some studies frequently detected species [20]. have reported a higher frequency in women, most likely be- – In recurrent disseminated PV, a newly proposed form of cause women seek medical care more often than men [9, 14, the disease, M. japonica and M. furfur were isolated more 15]. frequently [32]. However, in 2013, in patients with exten- sive PV,species other than those previously reported were Phototype not detected [28]. PV usually presents in dark phototypes, but this link is con- Notably, as shown in Table 2, M. pachydermatis and sidered to correspond to a more prominent appearance of the M. nana, which were initially isolated in animals, have also lesions; however, some studies do not support the tendency been isolated in PV lesions, as indicated in Table 1,wherewe towards hypopigmented lesions in individuals with darker show the Malassezia species isolated from PV lesions in stud- skin or that the predisposition is dependent on age or gender ies conducted in the last 5 years. •• [1 , 16]. To differentiate between Malassezia species, a combination Table 1 shows the characteristics of patients with PV in of biochemical, morphological, biological and molecular tests studies published in the last 5 years. is required. Morphologically, Malassezia yeasts measure 1.5– 10 μm, exhibit asexual reproduction with monopolar budding, have shapes varying from spherical to ovoid, and have a thick Aetiology (Mycological Characteristics) wall compared to other yeasts (measuring 0.12 μm), which accounts for up to 26–37% of the cell volume. Cultures should The genus Malassezia includes yeasts of the division be performed in special media, such as Sabouraud-dextrose Basidiomycota, subphylum Ustilaginomycotina, class supplemented with sterile olive oil, Dixon medium or its mod- Malasseziomycetes and family Malasseziaceae, most of ified formula, Leeming and Notman agar and Ushijima medi- which are dependent on lipids (except M. pachydermatis). um, except for the species M. pachydermatis, which is capable These yeasts are part of the microbiota of nearly the entire of growing in conventional media. The saprophytic (yeast) surface of the human skin, except for the soles of the feet phase requires the presence of fatty acids for its progression and are mainly found on areas such as the scalp, face and and yields mycelium (the opportunistic phase) under favorable trunk. Under certain conditions, these yeasts are associated conditions. To achieve this, temperatures between 30 and 35 °C with a broad spectrum of clinical entities, although PV is the and humidity must be supplied to the cultures, which should be most common disease caused by such agents and the only placed in plastic bags to prevent desiccation. Biochemical and disease for which Malassezia has been established as a caus- physiological tests and reagents, such as the catalase reaction, ative agent [1••, 26, 27]. β-glucosidase, polysorbate requirements 20, 40, 60, and 80 Curr Fungal Infect Rep (2019) 13:157 Table 1 Epidemiological characteristics and species of Malassezia in PV Author Country Year Number of Gender Age group with higher Most frequent clinical Most frequent anatomical Identified species Identification method patients (%) frequency (years) variant location Rodoplu et al. Turkey 2014 146 M=82.8 18–34 NR More than 1 area M. globosa 65.1% Catalase activity and [17] F=17.1 M. obtusa 17.4% β-glucosidase, M. japonica 7.4% SDA culture, assimilation of M. nana 3.7% cremophor EL, utilization of Tweens 20, 40, 60, and 80, precipitate production in mDixon – Xie et al. [18] China 2014 24 NR NR NR NR M. globosa 95.8% RT-PCR 168 M. restricta 91.7% M. dermatis 33.3% Ibekwe et al. Nigeria 2015 304 M=38.8 12–21 Hypopigmented Face M. furfur 81.7% PCR-RFLP [19] F=61.1 M. restricta 5.1% M. sympodialis 2.3% Heidrich et al. Brazil 2015 2239 M= 42 21–30 NR Trunk NR NR [1] F= 58 Sharma et al. India 2016 262 M=65.6 21–30 Hypopigmented Neck M. furfur 77.3% PCR-RFLP [10] F=34.4 M. globosa 12.4% Moallaei et al. Iran 2017 42 M=59.5 18–22 NR Neck M. restricta PCR- RFLP [20] F=40.5 (8.4%) M. globosa (6.2%) M. sympodialis (4.2%) M. furfur 3% Yahya et al. [15] Nigeria 2017 265 M=40.2 20–29 NR NR NR NR F=59.8 Elshabrawy et al.
Recommended publications
  • A Systematic Review of Diagnosis and Treatment Options for Tinea Imbricata
    Int. J. Life Sci. Pharma Res. 2019 Oct; 9(4): (L) 28-33 ISSN 2250-0480 Review Article Dermatology International Journal of Life science and Pharma Research A SYSTEMATIC REVIEW OF DIAGNOSIS AND TREATMENT OPTIONS FOR TINEA IMBRICATA RANA ABDULAZEEM AL-BASSAM1, BASMAH SALEM AL AFARI 1 AND MANAL HASSAN MOHAMED SALEM2* 1Intern doctor, Dar Al Uloom University Riyadh, Saudi Arabia., 2Mater degree of dermatology,venereology and andrology , Doctor Abdulazeem Albassam Medical Group, Department of Dermatology, Riyadh, Saudi Arabia ABSTRACT Tinea imbricata is a cutaneous fungal disease and sometimes called (Tokelau). The causative agent is a dermatophyte known as Trichophyton concentricum. It is an endemic in developing countries particularly in South Pacific, India, Central and South America, as well as Mexico. It is generally observed in people with poor living conditions and poor personal hygiene. Predisposing factors are hot weather, humidity, and host immunity in addition to genetic factors. The patients usually presented with concentric or lamellar skin lesions. The aim of this review is to highlight important information about microbial, clinical and therapeutic aspects of tinea imbricta. In this review, we search the literature to identify articles talking different aspects of tinea imbricta. The electronic search was performed in four databases to identify eligible articles in the literature. Electronic databases were searched including MEDLINE and EMBASE using PubMed search engine. In addition, Cochrane library and ovid was searched. The titles and abstracts of the resulted articles were screened to identify eligible studies. Based on the primary screening results the irrelevant studies, duplicated and reviews were excluded. Tinea imbricta is found to be endemic in 3 main geographical regions, Southwest Pacific, Southeast Asia, and Central and South America.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 7/60 (2006.01) G01N 33/53 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CI2Q 1/18 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (21) International Application Number: KM, ML, MR, NE, SN, TD, TG). PCT/US2017/063696 (22) International Filing Date: Published: 29 November 201 7 (29. 11.201 7) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/427,507 29 November 2016 (29. 11.2016) US 62/484,696 12 April 2017 (12.04.2017) US 62/53 1,767 12 July 2017 (12.07.2017) US 62/541,474 04 August 2017 (04.08.2017) US 62/566,947 02 October 2017 (02.10.2017) US 62/578,877 30 October 2017 (30.10.2017) US (71) Applicant: CIDARA THERAPEUTICS, INC [US/US]; 63 10 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US). (72) Inventors: BARTIZAL, Kenneth; 7520 Draper Avenue, Unit 5, La Jolla, CA 92037 (US). DARUWALA, Paul; 1141 Luneta Drive, Del Mar, CA 92014 (US). FORREST, Kevin; 13864 Boquita Drive, Del Mar, CA 92014 (US).
    [Show full text]
  • Seborrheic Dermatitis More Than Meets the Eye
    SEBORRHEIC DERMATITIS More than meets the eye Martijn Gerard Hendrik Sanders Financial support for the printing of this thesis was kindly provided by: La Roche-Posay UCB Chipsoft LEO Pharma Louis Widmer L’Oréal Lilly Merz Pharma Van der Bend B.V. Olmed ISBN: 978-94-6361-558-7 Cover illustration by Sara van der Linde Cover design, lay-out and printing by Optima Grafische Communicatie Copyright © M.G.H. Sanders, Rotterdam 2021 All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form by any means without permission from the author, or when appropriate, of the publisher of the publication. Seborrheic Dermatitis More than meets the eye Seborroïsch eczeem Niet alles is wat het lijkt Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. F.A. van der Duijn Schouten en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatvinden op donderdag 24 juni 2012 om 10:30 uur Door Martijn Gerard Hendrik Sanders geboren te Almelo PROMOTIECOMMISSIE Promotor: prof. dr. T.E.C. Nijsten Overige leden: prof. dr. E.P. Prens prof. dr. A.G. Uitterlinden prof. dr. J.L.W. Lambert Copromotor: dr. L.M. Pardo Cortes CONTENTS Chapter 1 General introduction 7 Chapter 2 Dermatological screening of a middle-aged and elderly population: 19 the Rotterdam Study Chapter 3 3.1 Prevalence and determinants of seborrheic dermatitis in a middle 29 aged and elderly population: the Rotterdam Study 3.2 Association between
    [Show full text]
  • Current Options in Antifungal Pharmacotherapy
    Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immuno- competent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug- interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections. Key Words: antifungal drugs, invasive fungal infection, amphotericin B, polyenes, invasive aspergillosis, liposomal amphotericin B, L-AmB. (Pharmacotherapy 2008;28(5):614–645) OUTLINE Icofungipen Polyenes Conclusion Mechanism of Action Invasive fungal infections continue to be asso- Clinical Efficacy ciated with high rates of morbidity and mortality Safety in both immunocompromised and immuno- Azoles competent hosts. Amphotericin B deoxycholate Mechanism of Action (AmBd) has been the cornerstone for treatment Clinical Efficacy of invasive fungal infections since the early Safety 1950s. However, new agents have emerged to Echinocandins manage these infections over the past 15 years Mechanism of Action (Figure 1). Although Candida species remain the Clinical Efficacy most common pathogens associated with fungal Safety disease, infections caused by Aspergillus and Investigational Antifungal Drugs and Other Cryptococcus sp, Zygomycetes, and the endemic Nonantifungal Agents fungi (Histoplasma, Blastomyces, and Coccidioides Monoclonal Antibody Against Heat Shock Protein 90 sp) also account for many fungal infections.
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.404,751 B2 Birnbaum Et Al
    USOO8404751B2 (12) United States Patent (10) Patent No.: US 8.404,751 B2 Birnbaum et al. (45) Date of Patent: Mar. 26, 2013 (54) SUBUNGUICIDE, AND METHOD FOR 5,696,105 A * 12/1997 Hackler ........................ 514f172 TREATING ONYCHOMYCOSIS 5,894,020 A 4, 1999 Concha 6,008,173 A * 12/1999 Chopra et al. ................ 51Of 152 6,043,063 A 3/2000 Kurdikar et al. (75) Inventors: Jay E. Birnbaum, Montville, NJ (US); 6,143,794. A 11/2000 Chaudhuri et al. Keith A. Johnson, Durham, NC (US) 6,162,420 A 12/2000 Bohn et al. 6,207,142 B1 3/2001 Oddset al. (73) Assignee: Hallux, Inc., Santa Ana, CA (US) 6,221,903 B1 4/2001 Courchesne 6,224,887 B1 5, 2001 Samour et al. (*)c Notice:- r Subject to any disclaimer, the term of this 6,264,9276,231,840 B1 7/20015, 2001 MonahanBuck patent is extended or adjusted under 35 6.361,785 B1 3/2002 Nair et al. U.S.C. 154(b) by 233 days. 6,733,751 B2 5, 2004 Farmer 6,846,837 B2 1/2005 Maibach et al. (21) Appl. No.: 12/606,324 6,878,365 B2 * 4/2005 Brehove .......................... 424,61 7,074,392 B1 7/2006 Friedman et al. 2002/017343.6 A1 11/2002 Sonnenberg et al. (22) Filed: Oct. 27, 2009 2002/0183387 A1 12/2002 Bogart 2003/OOOT939 A1 1/2003 Murad (65) Prior Publication Data 2003/0207971 A1* 11/2003 Stuartet al. ................... 524, 274 2004.0062733 A1 4/2004 Birnbaum US 201O/OO48724 A1 Feb.
    [Show full text]
  • Effect of Pramiconazole on Signs and Symptoms of Tinea Cruris/Corporis
    Open Label Phase IIa Trials to Evaluate the Effects of Short Term Oral Pramiconazole in Tinea Pedis and Tinea Cruris/Corporis 1Jacques Decroix, 2Jannie Ausma, 2Luc Wouters, 2Marcel Borgers, 2Lieve Vandeplassche 1Avenue du Parc 39, Mouscron, Belgium and 2Barrier Therapeutics, Geel, Belgium Introduction Efficacy Results Tinea Pedis Efficacy Results Tinea Cruris/Corporis Table 3: Effect of pramiconazole on signs and symptoms of tinea Pramiconazole, previously referred to as R126638, is a broad spectrum antifungal Table 1: Effect of pramiconazole on signs and symptoms of tinea pedis belonging to the class of triazoles. It has excellent potential for oral and topical cruris/corporis treatment of fungal infections of skin, hair, nails, oral and genital mucosa. In vitro data Day All Patients Cohort I Cohort II Day All Patients Cohort I Cohort II demonstrated its activity against dermatophytes (Trichophyton spp., Microsporum (3 & 5 days) (3 days) (5 days) (3 & 5 days) (3 days) (5 days) canis, Epidermophyton floccosum), yeasts and many other fungi. Furthermore, Total Signs & 1 9.9 (3-14) 10.2 (8-12) 9.5 (3-14) Total Signs & 1 5.8 (4-9) 6.1 (8-12) 5.6 (3-14) efficacy studies in animals provided evidence for a potent therapeutic effect of Symptoms 4/6 7.2 (2-11) <.001 7.8 (6-11) 0.004 6.6 (2-11) 0.002 Symptoms 4/6 4.8 (3-7) <.001 5.0 (6-11) 0.063 4.6 (2-11) 0.031 R126638 that proved to be 3- to 8-fold superior over that of itraconazole, especially Score** 14 3.4 (1-6) <.001 3.3 (2-5) 0.002 3.5 (1-6) 0.002 Score** 14 2.8 (2-4) <.001 2.9 (2-5) 0.004 2.7 (1-6) 0.004 for superficial fungal infections.
    [Show full text]
  • The Role of Dendritic Cells in the Innate Recognition of Pathogenic Fungi (A. Fumigatus, C. Neoformans and C. Albicans)
    SPECIAL FOCUS REVIEW: DENDRITIC CELLS Virulence 3:7, 635–646; November 15, 2012; G 2012 Landes Bioscience The role of dendritic cells in the innate recognition of pathogenic fungi (A. fumigatus, C. neoformans and C. albicans) Zaida G. Ramirez-Ortiz and Terry K. Means* Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy, and Immunology; Massachusetts General Hospital and Harvard Medical School; Charlestown, MA USA Keywords: plasmacytoid dendritic cells, conventional dendritic cells, fungi, Toll-like receptors, scavenger receptors Dendritic cells (DCs) are the bridge between the innate and The Big Three: Aspergillus fumigatus, Candida adaptive immune system. DCs are responsible for sensing and albicans and Cryptococcus neoformans patrolling the environment, initiating a host response and instructing the proper adaptive immune response against Increase in the incidence of fungal infections correlates with pathogens. Recent advances in medical treatments have led to increased use of immunosuppressive drugs, leading to the advances in medical treatment resulting in increased numbers of emergence of fungal species that cause life-threatening immune-compromised patients, particularly those suffering from infections in humans. Three of these opportunistic fungal AIDS, cancer patients receiving chemotherapy and those taking pathogens: Aspergillus fumigatus, Candida albicans and immunosuppressive drugs following solid organ transplantation.3 Cryptococcus neoformans pose the biggest concern for the Aspergillus fumigatus is the primary causative species of human immune-compromised host. Here we will review the interac- aspergillosis. On a daily basis, humans inhale hundreds of tions between DCs and these fungal pathogens, the receptors microscopic conidia or non-motile spores of this mold. These 2–3 expressed on DCs that mediate these responses and the mm conidia are small enough to bypass the mucosal barriers and signaling mechanisms that shape the adaptive host response.
    [Show full text]
  • International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 Coden: IJARQG(USA) Case Report
    Int. J. Adv. Res. Biol. Sci. (2016). 3(1): 13-16 International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 www.ijarbs.com Coden: IJARQG(USA) Case Report SOI: http://s-o-i.org/ 1.15/ijarbs-2016-3-1-3 A Case report of Recurrent Tinea cruris and Tinea corporis Dr. Bhawna Sharma1, Dr. Payal Dutta2, Dr. Gaurav Bhaskar3 and Dr. Neeru Bhaskar4 1MD Microbiology, MMIMSR Mullana, Ambala, Haryana 133007, India 2MD Microbiology, MMIMSR Mullana, Ambala, Haryana 133007, India 3DVD Dermatology and Venereology, Medical Director, B. S. D.Hospital, Karnal, Haryana. 132001. 4MD Biochemistry, MMIMSR Mullana, Ambala, Haryana 133007, India *Corresponding author: [email protected] Abstract Superficial fungal infections of the skin are a major health problem and are associated with morbidity due to chronic itching and inflammation of skin.1 Superficial fungal infections of skin are caused mainly by dermatophytes namely Trichophyton, Microsporum and Epidermophyton species and also due to Candida and Malessesiasp.2 Superficial dermatophytic infections has been classified according to the site of involvement. They affect 20%-30% of the world’s population and carries significant modbidity due to chronic itching and reduce the quality of life.1 Dermatophytes are aerobic fungi and feed on dead keratin on body so mainly infest skin, hair and nails that are rich in keratin. The classic presentation of dermatophytosis is that of an annular or ring-shaped red scaly plaque with central clearing, often associated with severe pruritus. Treatment includes systemic and topical antifungals with variable duration depending upon the site of infection and the antifungal chosen.
    [Show full text]
  • Severe Dermatophytosis and Acquired Or Innate Immunodeficiency
    Journal of Fungi Review Severe Dermatophytosis and Acquired or Innate Immunodeficiency: A Review Claire Rouzaud 1,*, Roderick Hay 2, Olivier Chosidow 3, Nicolas Dupin 4, Anne Puel 5, Olivier Lortholary 1,6,7 and Fanny Lanternier 1,6,7,* Received: 21 October 2015; Accepted: 14 December 2015; Published: 31 December 2015 Academic Editor: David S. Perlin 1 Centre d’Infectiologie Necker-Pasteur, Hôpital Necker Enfants Malades et Institut Imagine, APHP, Université Paris Descartes, Sorbonne Paris Cité, 75015 Paris, France; [email protected] 2 Dermatology Department, King’s College Hospital NHS Trust, London SE5 9RS, UK; [email protected] 3 Service de Dermatologie, Hôpital Henri Mondor, APHP, Université Paris-Est Créteil, 94010 Créteil, France; [email protected] 4 Service de Dermatologie, Hôpital Cochin, APHP, Université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France; [email protected] 5 Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM U1163, Hôpital Necker Enfants Malades et Institut Imagine, Université Paris Descartes, Sorbonne Paris Cité, 75015 Paris, France; [email protected] 6 Institut Pasteur, Centre National de Référence Mycoses Invasives, 75015 Paris, France 7 Institut Pasteur, Unité de Mycologie Moléculaire, CNRS URA3012, 75015 Paris, France * Correspondence: [email protected] (C.R.); [email protected] (F.L.); Tel.: +33-1-4449-5381 (C.R.); +33-1-4449-4429 (F.L.) Abstract: Dermatophytes are keratinophilic fungi responsible for benign and common forms of infection worldwide. However, they can lead to rare and severe diseases in immunocompromised patients. Severe forms include extensive and/or invasive dermatophytosis, i.e., deep dermatophytosis and Majocchi’s granuloma.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]